Nazartinib

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Advanced Solid Tumors Which Are cMET-dependentNon Small Cell Lung Cancer

Phase 1

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

TerminatedNCT02335944

Novartis PharmaceuticalsNon Small Cell Lung Cancer

Start: 2015-01-13End: 2020-11-10Updated: 2023-06-18

Phase 2

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Active, not recruitingNCT03040973

Novartis PharmaceuticalsAdvanced Solid Tumors Which Are cMET-dependent

Start: 2017-07-04End: 2027-07-30Updated: 2026-09-09

Related Papers

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

2024-06-221 citations

Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI.

Journal of Clinical Oncology2017-05-201 citations